Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21889199 | 0.87 | DGAT1 (0.45) | DGAT1ENPP3ENPP1MAOBPTGES | |
| SCHEMBL21889298 | 0.85 | DGAT1 (0.44) | DGAT1ENPP3ENPP1MAOBPTGES | |
| SCHEMBL21889821 | 0.85 | DGAT1 (0.44) | DGAT1ENPP3ENPP1MAOBPTGES | |
| SCHEMBL21889844 | 0.85 | DGAT1 (0.44) | DGAT1ENPP3ENPP1MAOBPTGES | |
| SCHEMBL21889556 | 0.84 | DGAT1 (0.33) | DGAT1MAOB | |
| SCHEMBL21889837 | 0.83 | AOC3 (0.46) | DGAT1ENPP3ENPP1MAOBPTGES | |
| SCHEMBL21914584 | 0.81 | NPC1 (0.44) | ENPP3ENPP1MAOBPTGESTP53 | |
| SCHEMBL16661083 | 0.80 | DGAT1 (0.46) | DGAT1ENPP3ENPP1MAOBPTGES | |
| SCHEMBL21889223 | 0.80 | DGAT1 (0.46) | DGAT1ENPP3ENPP1MAOBPTGES | |
| SCHEMBL21889304 | 0.79 | DGAT1 (0.45) | DGAT1ENPP3ENPP1MAOBPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198220-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-07-01 | — | — | US | disclosed |
| US-11001563-B2 | SSAO inhibitor | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-11 | — | — | US | disclosed |
| US-20200115352-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-16 | — | — | US | disclosed |
| EP-3626699-A1 | SSAO INHIBITOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001563-B2 | SSAO inhibitor | SSB, ASAH2, AOX1 | DGAT1 3115/4885ENPP3 497/4885ENPP1 462/4885 |
| US-20210198220-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | DGAT1 3115/4885ENPP3 497/4885ENPP1 462/4885 |
| US-20200115352-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | DGAT1 3115/4885ENPP3 497/4885ENPP1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.